Comparative study of helicobacter pylori eradication rates with 5-day quadruple concomitant therapy and 7-day standard triple therapy

Research output: Contribution to journalArticle

31 Citations (Scopus)


Background: Several studies have shown the superiority of concomitant quadruple therapy containing 3 antibiotics over triple therapy for Helicobacter pylori infection. The aim of this study was to compare concomitant quadruple therapy with standard triple therapy for first-line H. pylori eradication. Background: A total of 270 patients with proven H. pylori infection were randomly assigned to one of 2 regimens: amoxicillin 1000 mg with clarithromycin 500 mg and lansoprazole 30 mg twice daily for 7 days (triple therapy) or amoxicillin 1000 mg with clarithromycin 500 mg, metronidazole 500 mg, and lansoprazole 30 mg twice daily for 5 days (concomitant therapy). The success of eradication was evaluated 4 to 5 weeks after completion of treatment. Results: Eradication rates were 86.1% in the triple therapy and 91.4% in the concomitant therapy (per protocol), but the difference was not statistically significant. Mild adverse events were more frequently reported in the concomitant-therapy group (35.6%) than in the triple-therapy group (25.2%) (P=0.09). Conclusions: Five-day quadruple concomitant therapy eradicated H. pylori in over 90% of patients. Accordingly, concomitant therapy is thought to be a promising alternative to triple therapy as a first-line treatment regimen for H. pylori eradication.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalJournal of Clinical Gastroenterology
Issue number1
Publication statusPublished - 2013 Jan 1



  • Helicobacter pylori
  • combination
  • concomitant therapy
  • drug therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this